Celldex Therapeutics (CLDX) Shares Moved, So What Is Driving Attention Today?

Celldex Therapeutics (CLDX) has reported that its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab in chronic spontaneous urticaria met the primary and all key secondary endpoints, with clinically meaningful, statistically significant improvements in disease activity.

Celldex Therapeutics shares trade at US$32.41 after a sharp 30 day share price return decline of 18.22%. This is occurring even though the year to date share price return is up 19.99% and the 1 year total shareholder return of 28.15% points to momentum that has been building over a longer window.

Track how Celldex Therapeutics fits alongside other potential breakout opportunities in mast cell, autoimmune, and allergy treatments by scanning our hand picked 37 healthcare AI stocks.

The recent pullback in Celldex Therapeutics after strong Phase 3 data leaves an open question: Are investors reassessing the business, or just resetting sentiment before the valuation case is tested next?

Most Popular Narrative: 64% Undervalued

Celldex Therapeutics last closed at $32.41 while the most followed narrative anchors on a fair value of about $90.31. The story investors are weighing is whether the barzolvolimab franchise can grow into that gap using mast cell biology across multiple immune driven conditions.

Barzolvolimab’s long duration of complete responses in chronic spontaneous urticaria and sustained control of angioedema well after drug and tryptase levels normalize could support longer treatment courses or retreatment approaches that extend the revenue contribution per patient beyond what simple symptom control would suggest.

See why 0 investors see Celldex Therapeutics as 64% undervalued.

Result: Fair Value of $90.31 (UNDERVALUED)

Still, the recent prurigo nodularis miss and the ongoing deep losses reported in the first half of 2026 could both weaken confidence in the bullish Celldex Therapeutics narrative.

Find out about the key risks to this Celldex Therapeutics narrative.

Next Steps

If this mix of optimism and caution around Celldex Therapeutics feels familiar, treat it as your cue to review the numbers and sentiment yourself, then weigh both sides through the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Celldex Therapeutics?

If Celldex Therapeutics has your attention, do not stop there. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match your approach.

• Target resilient income by reviewing companies in the 7 dividend fortresses that aim to combine robust payouts with staying power through different market conditions.
• Hunt for quality on sale by checking the 32 high quality undervalued stocks that filters for strong fundamentals at prices that may not fully reflect them yet.
• Reduce downside surprises by focusing on the 31 resilient stocks with low risk scores where financial strength and lower risk scores take priority over hype.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com